Group 1 - China State Construction won multiple major projects with a total amount of 21.53 billion yuan, accounting for 1.0% of the audited revenue for 2024 [1] - Zhongtai Chemical's subsidiary has fully launched a methanol upgrading demonstration project, which will further reduce production costs [1] - Wide Special Materials expects a net profit increase of approximately 367.51% year-on-year for the first half of 2025, driven by improved demand and internal optimization [1][2] Group 2 - Longdi Group plans to exercise its preferential subscription rights to participate in the convertible bond issuance of its associate company, Yongqi Electronics, with an investment of no more than 89.249 million yuan [3] - Dayou Energy's subsidiary Mengjin Coal Mine has resumed production after a 38-day suspension due to an accident, with an annual capacity of 1.2 million tons [5] - Shanying International plans to repurchase shares worth between 500 million and 1 billion yuan, with a maximum repurchase price of 2.50 yuan per share [7] Group 3 - Huatai Securities has been approved to issue up to 10 billion yuan in technology innovation bonds to support investment in the technology innovation sector [9] - Weixin Kang's cooperative product, an injectable multivitamin, has passed the consistency evaluation, enhancing its market potential [10] - Jinpu Titanium's controlling shareholder will have 35 million shares auctioned, accounting for 3.55% of the company's total share capital [11] Group 4 - China Pharmaceutical plans to waive its preferential purchase rights for a 24% stake in Chongqing Medical Health Industry Co., with a base transfer price of 2.206 billion yuan [12] - Beijia Clean plans to reduce its shareholding by 1.99% due to funding needs [13] - Anpelon has obtained a design patent for a brake sensor, enhancing its technological capabilities [14] Group 5 - Zhongyue Holdings' subsidiary has received approval for a clinical trial application for a new drug, indicating progress in its pharmaceutical development [14] - Lijun Group's YJH-012 injection has been approved for clinical trials, showcasing its potential in treating gout [16] - Yageer has sold financial assets totaling 4.176 billion yuan, representing 10.13% of its audited net assets for 2024 [15] Group 6 - Tailing Micro expects a net profit increase of approximately 267% year-on-year for the first half of 2025, driven by customer demand and product sales [19] - Baotai plans to invest 287 million yuan to acquire a 51% stake in Shaanxi Wanhao Titanium Technology Co., enhancing its production capabilities [21] - Laime Pharmaceutical has received a drug registration certificate for azithromycin granules, expanding its product portfolio [23] Group 7 - KQ Bio has received approval for a new veterinary vaccine, marking a significant advancement in its product offerings [25] - Robotech signed a contract worth approximately 17.1 million euros, representing over 12.82% of its audited revenue for 2024 [26] - Alloy Investment is planning a control change, leading to a temporary suspension of its stock [27] Group 8 - Huabang Health's subsidiary has received approval for two dermatological drugs, indicating growth in its pharmaceutical pipeline [28] - Lingxiao Pump Industry plans to invest 60 million yuan in wealth management products, optimizing its financial strategy [29] - Jinzhong Technology has won projects totaling 113 million yuan, accounting for 6.39% of its expected revenue for 2024 [31] Group 9 - Yifan Pharmaceutical's subsidiary has received approval for a clinical trial of a growth hormone injection, indicating progress in its research and development [32] - Guiguan Electric plans to invest 395 million yuan in a photovoltaic project, reflecting its commitment to renewable energy [33] - Rili Technology intends to repurchase shares worth between 10 million and 20 million yuan, supporting its stock performance [34] Group 10 - Xingye Securities' chairman has resigned, leading to a change in leadership [35] - Jinko Solar has achieved third-party certification for its high-efficiency solar cells, setting a new industry record [37] - Changan Automobile's controlling shareholder has changed its name, reflecting a rebranding effort [38]

6月6日晚，白云山（600332）发布公告称，分公司白云山制药总厂收到国家药品监督管理局核准签发的 他达拉非片（2.5mg、5mg）《药品注册证书》。他达拉非是一种用于治疗男性勃起功能障碍（ED）的 磷酸二酯酶5（PDE5）抑制剂。 白云山：分公司收到药品注册证书 资料显示，白云山成立于1997年9月，主营业务是中西成药、化学原料药、天然药物、生物医药、化学 原料药中间体的研发、制造与销售；西药、中药和医疗器械的批发、零售和进出口业务；大健康产品的 研发、生产与销售；医疗服务、健康管理、养生养老等健康产业投资。 所属行业：医药生物–中药Ⅱ–中药Ⅲ 华银电力：拟投资13.98亿元开发新能源发电项目 6月6日晚，华银电力（600744）发布公告称，公司拟投资建设株洲市醴陵市沩山风电场项目、郴州市桂 东县普洛风力发电项目、衡南县向阳光伏发电项目一期工程，三个项目装机规模共计230兆瓦，总投资 额约为13.98亿元。资金来源包括资本金和银行贷款。项目已取得核准（备案）证明并获取建设指标。 资料显示，华银电力成立于1993年3月，主营业务是火力发电业务，同时经营水电、风电、太阳能业务 以及电力销售业务。 福元医药：盐酸 ...

中国化学：控股股东获得增持资金贷款支持 太阳电缆：股东拟减持不超过3%公司股份 5月29日，太阳电缆（002300）发布公告称，公司股东福建亿力集团有限公司计划自公告披露之日起15 个交易日后的3个月内，通过集中竞价交易或大宗交易方式减持公司股份不超过2167万股，占公司总股 本的3%。减持原因为股东自身经营需要。 资料显示，太阳电缆成立于1994年7月，主营业务是电线电缆的生产、销售。 所属行业：电力设备–电网设备–线缆部件及其他 5月29日，中国化学（601117）发布公告称，公司控股股东中国化学工程集团有限公司获得中国工商银 行股份有限公司的贷款承诺，借款额度不超过5.4亿元，专项用于实施增持计划。此前，中国化学工程 于2025年4月12日宣布拟于12个月内增持公司股份，增持金额不低于3亿元，不超过6亿元。 资料显示，中国化学成立于2008年9月，主营业务是建筑工程业务、实业、现代服务业。 所属行业：建筑装饰–专业工程–化学工程 棕榈股份：因借贷纠纷提起诉讼 涉案金额超1.49亿元 5月29日，棕榈股份（002431）发布公告称，公司因与山东胜伟盐碱地科技有限公司等多家公司及个人 的借贷纠纷，向河南省郑 ...

中国建筑：1-4月新签合同总额1.52万亿元 5月16日晚，中国建筑（601668）发布公告称，公司1-4月新签合同总额为1.52万亿元，同比增长2.8%。 资料显示，中国建筑成立于2007年12月，主营业务是房地产开发、融投资建造、城镇综合建设等领域。 所属行业：建筑装饰–房屋建设Ⅱ–房屋建设Ⅲ 资料显示，宁波海运成立于1997年4月，主营业务是水路货物运输业务、收费公路运营业务。 所属行业：交通运输–航运港口–航运 铭普光磁：取得一项发明专利证书 5月16日晚，铭普光磁（002902）发布公告称，公司取得一项发明专利证书，发明名称为"一种磁粉芯及 其制备方法"。该专利涉及磁性材料技术领域，提供了一种磁粉芯的制备方法，能够在非晶磁粉表面形 成均匀致密且不易破裂的绝缘层。 阳普医疗：全资子公司取得医疗器械经营许可证 5月16日晚，阳普医疗（300030）发布公告称，全资子公司阳普医疗（湖南）有限公司于2025年5月8日 取得郴州市市场监督管理局签发的《医疗器械经营许可证》，许可期限至2030年5月7日。同时，公司于 2025年5月6日取得《第二类医疗器械经营备案凭证》。这将使湖南阳普能够开展医疗器械批零兼营业 ...

公司研究 2025.03.10 龙元建设（ 600491） 公司点评报告 定增方案更新，静待审核落地 方 正 证 券 研 究 所 证 券 研 究 报 告 分析师 | 刘清海 | 登记编号：S1220523090001 | | --- | --- | | 张其超 | 登记编号：S1220524090002 | 强烈推荐 ( 维 持 ) | 公 | 司 | 信 | 息 | | | --- | --- | --- | --- | --- | | 行业 | | | | 房屋建设Ⅲ | | 最新收盘价(人民币/元) | | | | 3.96 | | 总市值(亿)(元) | | | | 60.58 | | 52 周最高/最低价(元) | | | | 4.51/2.37 | 历史表现 -20% -5% 10% 25% 40% 24/3/10 24/6/9 24/9/8 24/12/8 龙元建设 沪深300 数据来源：wind 方正证券研究所 相关研究 《龙元建设(600491)：业绩大幅减亏，定增落地 在望》2025.01.21 《龙元建设(600491)：杭州车路云试点加速，公 司有望获得订单》2024.12.21 盈利 ...